TL;DR
CMS announced the third round of drugs selected for Medicare price negotiation — 15 medications covering diabetes, cancer, and cardiovascular disease.
MSM Perspective
AP reported the drug list as a health policy development.
X Perspective
X's health policy community celebrated the expansion while noting that negotiated prices don't take effect until 2028 — patients are paying full price for two more years.
The Centers for Medicare & Medicaid Services announced Friday that 15 additional drugs have been selected for direct price negotiation under the Inflation Reduction Act, bringing the total to 25 across three rounds. The new selections include treatments for Type 2 diabetes, breast cancer, and heart failure. [1]
Negotiated prices will not take effect until 2028. Medicare beneficiaries will continue paying current prices for the next two years.
-- NORA WHITFIELD, Chicago